Multi-omics Profiling: the Way Towards Precision Medicine in Metabolic Diseases

Overview

Journal J Mol Cell Biol

Publisher Oxford University Press

Specialty Molecular Biology

Date 2021 Aug 18

PMID 34406397

Citations 26

Authors

Cheng Hu

Weiping Jia

Affiliations

Soon will be listed here.

Abstract

Metabolic diseases including type 2 diabetes mellitus (T2DM), non-alcoholic fatty liver disease (NAFLD), and metabolic syndrome (MetS) are alarming health burdens around the world, while therapies for these diseases are far from satisfying as their etiologies are not completely clear yet. T2DM, NAFLD, and MetS are all complex and multifactorial metabolic disorders based on the interactions between genetics and environment. Omics studies such as genetics, transcriptomics, epigenetics, proteomics, and metabolomics are all promising approaches in accurately characterizing these diseases. And the most effective treatments for individuals can be achieved via omics pathways, which is the theme of precision medicine. In this review, we summarized the multi-omics studies of T2DM, NAFLD, and MetS in recent years, provided a theoretical basis for their pathogenesis and the effective prevention and treatment, and highlighted the biomarkers and future strategies for precision medicine.

Citing Articles

Harnessing exercise to combat chronic diseases: the role of Drp1-Mediated mitochondrial fission.

Sun Y, He J, Bao L, Shi X, Wang J, Li Q Front Cell Dev Biol. 2025; 13:1481756.

PMID: 40078364 PMC: 11897009. DOI: 10.3389/fcell.2025.1481756.

Harnessing Pharmacomultiomics for Precision Medicine in Diabetes: A Comprehensive Review.

Dhieb D, Mustafa D, Hassiba M, Alasmar M, Elsayed M, Musa A Biomedicines. 2025; 13(2).

PMID: 40002860 PMC: 11853021. DOI: 10.3390/biomedicines13020447.

Advancements in precision medicine: multi-omics approach for tailored metformin treatment in type 2 diabetes.

Anwardeen N, Naja K, Elrayess M Front Pharmacol. 2024; 15:1506767.

PMID: 39669200 PMC: 11634602. DOI: 10.3389/fphar.2024.1506767.

Integrative analysis of toxicometabolomics and toxicoproteomics data: new molecular insights into thiazolidinedione-induced cardiotoxicity.

Al Sultan A, Rattray Z, Rattray N Metabolomics. 2024; 21(1):1.

PMID: 39636558 PMC: 11621136. DOI: 10.1007/s11306-024-02201-3.

Novel loci linked to serum lipid traits are identified in a genome-wide association study of a highly admixed Brazilian population - the 2015 ISA Nutrition.

Leite J, Pereira J, Alves de Souza C, Soler J, Mingroni-Netto R, Fisberg R Lipids Health Dis. 2024; 23(1):229.

PMID: 39060932 PMC: 11282745. DOI: 10.1186/s12944-024-02085-1.

References

Prasad R, Groop L . Genetics of type 2 diabetes-pitfalls and possibilities. Genes (Basel). 2015; 6(1):87-123. PMC: 4377835. DOI: 10.3390/genes6010087. View

Xu Y, Zalzala M, Xu J, Li Y, Yin L, Zhang Y . A metabolic stress-inducible miR-34a-HNF4α pathway regulates lipid and lipoprotein metabolism. Nat Commun. 2015; 6:7466. PMC: 4479415. DOI: 10.1038/ncomms8466. View

Newgard C . Interplay between lipids and branched-chain amino acids in development of insulin resistance. Cell Metab. 2012; 15(5):606-14. PMC: 3695706. DOI: 10.1016/j.cmet.2012.01.024. View

Saklayen M . The Global Epidemic of the Metabolic Syndrome. Curr Hypertens Rep. 2018; 20(2):12. PMC: 5866840. DOI: 10.1007/s11906-018-0812-z. View

Zeng Y, Mtintsilana A, Goedecke J, Micklesfield L, Olsson T, Chorell E . Alterations in the metabolism of phospholipids, bile acids and branched-chain amino acids predicts development of type 2 diabetes in black South African women: a prospective cohort study. Metabolism. 2019; 95:57-64. DOI: 10.1016/j.metabol.2019.04.001. View

Lu J, Wang L, Li M, Xu Y, Jiang Y, Wang W . Metabolic Syndrome Among Adults in China: The 2010 China Noncommunicable Disease Surveillance. J Clin Endocrinol Metab. 2016; 102(2):507-515. DOI: 10.1210/jc.2016-2477. View

Miao F, Wu X, Zhang L, Yuan Y, Riggs A, Natarajan R . Genome-wide analysis of histone lysine methylation variations caused by diabetic conditions in human monocytes. J Biol Chem. 2007; 282(18):13854-63. DOI: 10.1074/jbc.M609446200. View

Duong J, Kumar S, Kirkpatrick C, Greenup L, Arora M, Lee T . Population pharmacokinetics of metformin in healthy subjects and patients with type 2 diabetes mellitus: simulation of doses according to renal function. Clin Pharmacokinet. 2013; 52(5):373-84. DOI: 10.1007/s40262-013-0046-9. View

Marselli L, Thorne J, Dahiya S, Sgroi D, Sharma A, Bonner-Weir S . Gene expression profiles of Beta-cell enriched tissue obtained by laser capture microdissection from subjects with type 2 diabetes. PLoS One. 2010; 5(7):e11499. PMC: 2903480. DOI: 10.1371/journal.pone.0011499. View

10.

Zou J, Huss M, Abid A, Mohammadi P, Torkamani A, Telenti A . A primer on deep learning in genomics. Nat Genet. 2018; 51(1):12-18. PMC: 11180539. DOI: 10.1038/s41588-018-0295-5. View

11.

Jiao N, Baker S, Chapa-Rodriguez A, Liu W, Nugent C, Tsompana M . Suppressed hepatic bile acid signalling despite elevated production of primary and secondary bile acids in NAFLD. Gut. 2017; 67(10):1881-1891. DOI: 10.1136/gutjnl-2017-314307. View

12.

Pirola C, Sookoian S . Multiomics biomarkers for the prediction of nonalcoholic fatty liver disease severity. World J Gastroenterol. 2018; 24(15):1601-1615. PMC: 5910543. DOI: 10.3748/wjg.v24.i15.1601. View

13.

Murri M, Insenser M, Luque M, Tinahones F, Escobar-Morreale H . Proteomic analysis of adipose tissue: informing diabetes research. Expert Rev Proteomics. 2014; 11(4):491-502. DOI: 10.1586/14789450.2014.903158. View

14.

Younossi Z, Baranova A, Ziegler K, Del Giacco L, Schlauch K, Born T . A genomic and proteomic study of the spectrum of nonalcoholic fatty liver disease. Hepatology. 2005; 42(3):665-74. DOI: 10.1002/hep.20838. View

15.

Gangarapu V, Ince A, Baysal B, Kayar Y, Kilic U, Gok O . Efficacy of rifaximin on circulating endotoxins and cytokines in patients with nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol. 2015; 27(7):840-5. DOI: 10.1097/MEG.0000000000000348. View

16.

Krawczyk M, Jimenez-Aguero R, Alustiza J, Emparanza J, Perugorria M, Bujanda L . PNPLA3 p.I148M variant is associated with greater reduction of liver fat content after bariatric surgery. Surg Obes Relat Dis. 2016; 12(10):1838-1846. DOI: 10.1016/j.soard.2016.06.004. View

17.

Baselli G, Dongiovanni P, Rametta R, Meroni M, Pelusi S, Maggioni M . Liver transcriptomics highlights interleukin-32 as novel NAFLD-related cytokine and candidate biomarker. Gut. 2020; 69(10):1855-1866. PMC: 7497582. DOI: 10.1136/gutjnl-2019-319226. View

18.

Emdin C, Khera A, Natarajan P, Klarin D, Zekavat S, Hsiao A . Genetic Association of Waist-to-Hip Ratio With Cardiometabolic Traits, Type 2 Diabetes, and Coronary Heart Disease. JAMA. 2017; 317(6):626-634. PMC: 5571980. DOI: 10.1001/jama.2016.21042. View

19.

Meigs J, Cupples L, Wilson P . Parental transmission of type 2 diabetes: the Framingham Offspring Study. Diabetes. 2000; 49(12):2201-7. DOI: 10.2337/diabetes.49.12.2201. View

20.

Mahana D, Trent C, Kurtz Z, Bokulich N, Battaglia T, Chung J . Antibiotic perturbation of the murine gut microbiome enhances the adiposity, insulin resistance, and liver disease associated with high-fat diet. Genome Med. 2016; 8(1):48. PMC: 4847194. DOI: 10.1186/s13073-016-0297-9. View